Project Grant R21OD037870
- Federal Grant Award Summary The Ohio State University Office of Sponsored Programs received a $419,674 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective May 1, 2026, with completion targeted for January 31, 2031. The award funds fundamental research on the structure and mechanism of gene regulation by small noncoding RNAs in humans, specifically examining microRNAs (miRNAs) and...
- Federal Project Grant Award Summary The Ohio State University received a $416,726 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded September 11, 2025, with completion targeted for August 31, 2030. The project focuses on developing mass spectrometry-based technologies to enable chemical analysis of organoids—three-dimensional cell cultures derived from human or animal tissues—with...
- Federal Project Grant Award Summary The Ohio State University received a $2,130,924 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2029. This award supports fundamental research into developmental regulation of oscillatory gene expression, specifically investigating the segmentation clock mechanism that controls somitogenesis—the...
- Federal Project Grant Award Summary The Ohio State University received a $410,893 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded March 1, 2026, with completion targeted for December 31, 2030. This award supports research to discover and characterize phosphonic acid natural products (NPs) through genomics-accelerated approaches. The project aims to establish fundamental genetic,...
- Federal Project Grant Award Summary The Ohio State University received a $382,823 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective July 1, 2026 through June 30, 2031. The award funds development of Silicon-based Light-Enabled Active Potentiometry (SILEAP), a transformative analytical platform designed to address critical limitations in current biomedical imaging technologies....
- Federal Project Grant Award Summary The Ohio State University received a $159,075 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective August 1, 2025, through July 31, 2027. The award funds the validation of the MIRAD (Micro-RNA Assay for Radiation Dosimetry) assay as a rapid biodosimetry tool for radiological and nuclear mass casualty triage applications in pediatric and geriatric...
- Federal Project Grant Award Summary The Ohio State University Office of Sponsored Programs received a $433,125 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective June 1, 2026, with completion targeted for January 31, 2031. The award supports investigator-initiated research to understand metabolic reprogramming in reparative macrophages and its relationship to epigenetic...
- Federal Grant Award Summary The Ohio State University received a $441,030 Project Grant award from the National Science Foundation's Division of Integrative Organismal Systems under the Biological Sciences program (CFDA 47.074) for collaborative research examining transgenerational plasticity and parental environmental cues. The award, issued December 1, 2025, with completion targeted for November 30, 2028, supports both theoretical modeling and laboratory experimentation investigating how...
- Federal Grant Award Summary The Ohio State University received a $153,169 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), awarded on August 15, 2025, with a completion date of July 31, 2027. This research initiative develops a rapid, non-invasive triage method using Raman spectroscopy and artificial intelligence to assess radiation exposure in mass casualty scenarios resulting from nuclear reactor...
- Federal Grant Award Summary The Ohio State University Office of Sponsored Programs received a $249,000 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on August 22, 2025, with a completion date of July 31, 2028. This grant funds fundamental research investigating the role of RNase L (ribonuclease L) host messenger RNA (mRNA) cleavage in viral infections, specifically examining how...
The Ohio State University, Office of Sponsored Programs, received a $433,125 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Research Infrastructure Programs (CFDA 93.351) on July 1, 2026, with a completion date of June 30, 2028. The award funds development of a novel epitope-tagged estrogen receptor-beta (ERβ) mouse model using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) methodology. This model incorporates an eleven amino acid HiBiT peptide tag into the murine ERβ gene within its endogenous genomic context, enabling unambiguous and sensitive detection of ERβ protein levels in living organisms using validated, commercially available detection technology. The project addresses a critical research infrastructure gap by providing the scientific community with a validated animal model and biological resource to facilitate study of estrogen receptor-beta across multiple disease areas, including cardiovascular, metabolic, inflammatory, and neoplastic diseases. The model will enable researchers to reliably characterize ERβ protein expression changes in disease states, thereby supporting preclinical development of selective ERβ agonists and resolving existing confusion surrounding this receptor's role in disease biology. This research resource is intended for broad dissemination and application across multiple NIH institutes and organ systems, consistent with the Research Infrastructure Programs' mission to support cutting-edge research models and resources.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $433.1k | 6/26/26 |